

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re: Application of DEBINSKI et al.

Serial No.:

10/075,499

D.1 10.0000

Examiner:

SEP 0 3 2002

Date Filed:

February 12, 2002

Group:

TECH CENTER 1600/2900

For:

FRA-1 EXPRESSION IN BRAIN CANCER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on September 25, 2022

Stanley A. Kim, Ph.D., Esq.

_Reg. No. 42,730

TRANSMITTAL LETTER

Commissioner for Patents Washington, DC 20231

Dear Sir:

Please find enclosed for filing the following:

X Information Disclosure Statement, with PTO-1449, and references; and

X 1 postcard.

Although no fee is believed due, please charge any underpayment to Deposit Account No.

50-0951. This letter is submitted in duplicate.

Respectfully submitted,

AKERMAN SENTERFITT

Dated: September 25, 2002

Stanley A Kim, Ph.D., Esq.

Registration No. 42,730

222 Lakeview Avenue, Suite 400

P.O. Box 3188

West Palm Beach, FL 33402-3188

Tel: 561-653-5000

Docket No. 6460-40

TO THE PARTY OF TH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of DEBINSKI et al.

Serial No.:

10/075,499

Examiner:

RECEIVED

SEP 0 3 2002

Date Filed:

February 12, 2002

Group:

TECH CENTER 1600/2900

For:

FRA-1 EXPRESSION IN BRAIN CANCER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on **September 25**, 2007.

Stanley A. Kim, Ph.D., Esq.

_Reg. No. 42,730

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Dear Sir:

Pursuant to the Duty to Disclose under 37 CFR 1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed.

The claimed invention is believed patentable over the disclosures enclosed. This citation is intended to give the Examiner an opportunity to make an independent evaluation. No representations are made regarding these materials.

Respectfully submitted,

AKERMAN SENTERFITT

Dated: Soplember 25, 2002

Standey A. Kim, Ph.D., Esq.

Registration No. 42,730

222 Lakeview Avenue, Suite 400

P.O. Box 3188

West Palm Beach, FL 33402-3188

Tel: 561-653-5000

Sheet _1_ of _ 1 orn#353-1449 ATTY. DOCKET NO. APPLICATION NO. U.S. DEPARTMENT OF COMMERCE 6460-40 10/075,499 PATENT AND TRADEMARK OFFICE (Rev. 2-88) INFORMATION DISCLOSURE STATEMENT APPLICANT BY APPLICANT Debinski et al. FILING DATE GROUP (Use several sheets if necessary) February 12, 2002 U.S. PATENT DOCUMENTS EXAMINER'S DOCUMENT DATE NAME CLASS SUBCLASS FILING DATE INITIAL NUMBER IF APPROPRIATE 6,124,133 9/26/00 Taylor et al. NTER 1600/2900 FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUBCLASS TRANSLATION NUMBER YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bhattacharya et al., "Regulation of the Urokinase-type Plasminogen Activator Receptor Gene in Different Grades of Human Glioma Cell Lines," Clinical Cancer Research, 7: 267-276, 2001 Won et al., "Stimulation of astrocyte-enriched culture with arachidonic acid increases proenkephalin mRNA: involvement of proto-oncoprotein and mitogen activated protein kinases," Molecular Brain Research, 76: 396-406, 2000 Kustikova et al., "Fra-1 Induces Morphological Transformation and Increases In Vitro Invasiveness and Motility of Epitheliod Adenocarcinoma Cells," Molecular and Cellular Biology, 18: 7095-7105, 1998 Chiappetta et al., "FRA-1 Expression in Hyperplastic and Neoplastic Thyroid Diseases1," Clinical Cancer

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Debinski et al., "VEGF-D is an X-linked/AP-1 Regulated Putative Onco-angiogen in Human Glioblastoma

DATE CONSIDERED

Research, 6: 4300-4307, 2000

Multiforme," Molecular Medicine 7: 598-608, 2001

EXAMINER